Shanghai Abelzeta Ltd.
Clinical trials sponsored by Shanghai Abelzeta Ltd., explained in plain language.
-
New cell therapy aims to control Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment called A-CAR032 in 27 men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread to other parts of the body. The treatment uses the patient's own immune cells, modified to better recognize …
Phase: PHASE1 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated May 01, 2026 15:56 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is t…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Engineered immune cells take on tough lung cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called C-CAR031 for people with advanced squamous cell lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main g…
Phase: PHASE1 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC